Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Methotrexate pulmonary toxicity

G W Cannon1

  • 1Salt Lake City Veterans Affairs Medical Center, Utah, USA.

Rheumatic Diseases Clinics of North America
|November 15, 1997
PubMed
Summary
This summary is machine-generated.

Methotrexate (MTX) can cause serious lung disease in patients with rheumatic conditions. Early recognition of symptoms like shortness of breath and cough is crucial for prompt diagnosis and treatment to improve outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Post-traumatic stress disorder and serum cytokine and chemokine concentrations in patients with rheumatoid arthritis<sup>✰</sup>.

Seminars in arthritis and rheumatism·2019
Same author

A comparison of electronic and manual fracture risk assessment tools in screening elderly male US veterans at risk for osteoporosis.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2017
Same author

Cost-effectiveness of training rural providers to identify and treat patients at risk for fragility fractures.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2014
Same author

Risk of hospitalized bacterial infections associated with biologic treatment among US veterans with rheumatoid arthritis.

Arthritis care & research·2014
Same author

Folic acid pathway single nucleotide polymorphisms associated with methotrexate significant adverse events in United States veterans with rheumatoid arthritis.

Clinical and experimental rheumatology·2014
Same author

Poor to modest agreement between rheumatoid arthritis response measures in clinical practice.

Clinical and experimental rheumatology·2009
Same journal

Bridging the Divide in Global Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Foreword.

Rheumatic diseases clinics of North America·2026
Same journal

Pulmonary Complications of Biological Therapies in Inflammatory and Autoimmune Diseases.

Rheumatic diseases clinics of North America·2026
Same journal

Artificial Intelligence and Social Determinants of Health.

Rheumatic diseases clinics of North America·2026
Same journal

Updates in Ultrasound in Rheumatology.

Rheumatic diseases clinics of North America·2026
Same journal

Health Systems Strengthening to Promote Access to Care for Rheumatic and Musculoskeletal Diseases Globally.

Rheumatic diseases clinics of North America·2026
See all related articles

Area of Science:

  • Pulmonology
  • Rheumatology
  • Clinical Pharmacology

Background:

  • Methotrexate (MTX) is a common treatment for rheumatic diseases.
  • Drug-induced pulmonary disease is a recognized, potentially fatal complication of MTX therapy.
  • Awareness among physicians is critical for managing MTX-treated patients.

Purpose of the Study:

  • To highlight the importance of early recognition and evaluation of pulmonary symptoms in patients receiving MTX.
  • To inform healthcare providers about the clinical presentation and management of MTX-induced pulmonary toxicity.

Main Methods:

  • Review of clinical presentation, diagnostic approaches, and management strategies for MTX-induced pulmonary disease.
  • Emphasis on prompt evaluation of new pulmonary symptoms, including physical examination and chest radiography.

Related Experiment Videos

  • Discussion of differential diagnoses, including underlying rheumatic disease, infection, and other conditions.

    • Main Results:

    • Characteristic symptoms include shortness of breath, nonproductive cough, fatigue, and fever.
    • Abnormal chest radiography findings warrant MTX discontinuation and further investigation.
    • Most patients recover with appropriate supportive care, including hospitalization and corticosteroids for severe cases.

    Conclusions:

    • MTX-induced pulmonary toxicity is a significant risk that requires vigilant monitoring.
    • Prompt diagnosis and management, including MTX withdrawal and supportive care, are essential.
    • Patient education regarding potential pulmonary symptoms is vital for early intervention.